151 related articles for article (PubMed ID: 28516432)
1. Measurement of piperacillin plasma concentrations in cancer patients with suspected infection.
Rachow T; Schlüter V; Bremer-Streck S; Lindig U; Scholl S; Schlattmann P; Kiehntopf M; Hochhaus A; von Lilienfeld-Toal M
Infection; 2017 Oct; 45(5):629-636. PubMed ID: 28516432
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment.
Murao N; Ohge H; Ikawa K; Watadani Y; Uegami S; Shigemoto N; Shimada N; Yano R; Kajihara T; Uemura K; Murakami Y; Morikawa N; Sueda T
Int J Antimicrob Agents; 2017 Sep; 50(3):393-398. PubMed ID: 28694230
[TBL] [Abstract][Full Text] [Related]
3. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Pharmacodynamics of Piperacillin/Tazobactam in Patients with Nosocomial Infections.
Chen R; Qian Q; Sun MR; Qian CY; Zou SL; Wang ML; Wang LY
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):363-72. PubMed ID: 25894901
[TBL] [Abstract][Full Text] [Related]
5. Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review.
Yusuf E; Spapen H; Piérard D
J Crit Care; 2014 Dec; 29(6):1089-95. PubMed ID: 25179412
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
[TBL] [Abstract][Full Text] [Related]
7. Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units.
Chan JD; Dellit TH; Lynch JB
J Intensive Care Med; 2018 Feb; 33(2):134-141. PubMed ID: 28486867
[TBL] [Abstract][Full Text] [Related]
8. Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients.
Petersson J; Giske CG; Eliasson E
Acta Anaesthesiol Scand; 2016 Nov; 60(10):1425-1436. PubMed ID: 27655029
[TBL] [Abstract][Full Text] [Related]
9. [Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperacillin/tazobactam:prolonged vs. regular infusion].
Lü Y; Yan Z; Wang DH; Dong WL; Yang Y; Xia R
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):479-83. PubMed ID: 24021044
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?
Öbrink-Hansen K; Juul RV; Storgaard M; Thomsen MK; Hardlei TF; Brock B; Kreilgaard M; Gjedsted J
Antimicrob Agents Chemother; 2015 Nov; 59(11):7018-26. PubMed ID: 26349823
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
Varghese JM; Jarrett P; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
[TBL] [Abstract][Full Text] [Related]
13. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
Boselli E; Breilh D; Rimmelé T; Guillaume C; Xuereb F; Saux MC; Bouvet L; Chassard D; Allaouchiche B
Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
Cies JJ; Shankar V; Schlichting C; Kuti JL
Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
[TBL] [Abstract][Full Text] [Related]
15. Variability of piperacillin concentrations in relation to tazobactam concentrations in critically ill patients.
Zander J; Döbbeler G; Nagel D; Scharf C; Huseyn-Zada M; Jung J; Frey L; Vogeser M; Zoller M
Int J Antimicrob Agents; 2016 Oct; 48(4):435-9. PubMed ID: 27476810
[TBL] [Abstract][Full Text] [Related]
16. Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration?
Roberts JA; Roberts MS; Robertson TA; Dalley AJ; Lipman J
Crit Care Med; 2009 Mar; 37(3):926-33. PubMed ID: 19237898
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH).
van der Werf TS; Mulder PO; Zijlstra JG; Uges DR; Stegeman CA
Intensive Care Med; 1997 Aug; 23(8):873-7. PubMed ID: 9310805
[TBL] [Abstract][Full Text] [Related]
19. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics.
Kobayashi I; Ikawa K; Nakamura K; Nishikawa G; Kajikawa K; Yoshizawa T; Watanabe M; Kato Y; Zennami K; Kanao K; Tobiume M; Yamada Y; Mitsui K; Narushima M; Morikawa N; Sumitomo M
J Infect Chemother; 2015 Aug; 21(8):575-80. PubMed ID: 26050020
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intraperitoneal piperacillin/tazobactam in patients on peritoneal dialysis with and without pseudomonas peritonitis.
Zaidenstein R; Weissgarten J; Dishi V; Koren M; Soback S; Gips M; Averbuch Z; Simantov R; Assulin E; Golik A
Perit Dial Int; 2000; 20(2):227-31. PubMed ID: 10809248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]